British Biotech: Biotech-Perle aus England - 500 Beiträge pro Seite

[Meister Glanz]

Schaut euch mal die Seite an und die Partner (Schering, etc)!

[omnipotentus]

Meister Glanz, du machst zwar zu viele Treats auf, aber irgentwo hast du recht. Vonn der Bewertung ist BBP mit einen KUV von 2.8 ziemlich billig im verhältniss zu anderen.

[supernemaxman]

jetzt wird man BBP, nach super Zahlen, wieder entdecken und dann schaun mer mal...

[gottesanbeter]

nun ja, der langzeitchart sieht zwar nicht gut aus, aber auf diesem Niveau ist die aktie ein absoluter Kauf außerdem hat sich ein sehr starker boden gebildet und BBP hat Zahlen herraus gegeben, die für sich sprechen.

[bastiman]

die zahlen sind gut, aber man muß den wert erstmal kennen!

[AARating]

BBP ist absolut unter Wert, die haben potential bis über 4€.
dass wären 1500%

[bastiman]

Die amerikanische Investmentbank Goldman Sachs hat ihre Einstufung "Market Outperformer" für die Aktien der britischen
Biotech-Firma British Biotech ( Kurse, News, Diskussion ) wiederholt. Anlässlich der Vorlage der Jahreszahlen hat das
Unternehmen einen überraschend positiven Überblick zu den aktuellen Forschungsprojekten geliefert, schreiben die Analysten in
einer am Montag veröffentlichten Kurzstudie. Insgesamt werden im laufenden Jahr fünf bis sechs Medikamente in die klinische
Erprobung eintreten. Kursziel für die Aktie sei 48 Pence.

Während sich die Börsianer bei der Beurteilung des Unternehmens fast ausschließlich auf das Medikament Marimastat
konzentrierten, habe British Biotech einen Bestand neuer Produktkandidaten aufgebaut. Positiv heben die Analysten den
reduzierten Liquiditätsverbrauch des Unternehmens hervor.

Der Markt sollte nun das Scheitern Marimastats akzeptieren, meinen die Analysten. Die neuen Medikamente, die sich derzeit in
der Erprobung befänden, se ien vielversprechender. Die Arznei Marimastat hatte in vier von vier klinischen Tests keine Wirkung
gezeigt.

[Meister Glanz]

Kaufen bevor es zu spät ist!

[AARating]

Den Wert muß man haben!

[Meister Glanz]

Heute gings wieder ein bisschen nach unten!

[andeo]

@ unglanz, kannst du auch mal was fundiertes von dir geben, als überall nur zu schwafeln.

[DrLuck]

@MG

Kannst Du bitte die URL von BBIO hier reinstellen. ich finde sie nicht mehr. Auch die der Partner?

TIA

cu DrLuck

[Meister Glanz]

@ DrLuck

ich weiß auch nicht mehr wo ich die herhatte, strenge mich aber an, morgen oder am Samstag hab ichs!

[DrLuck]

http://www.britishbiotech.com/index.html

Da steht aber nichts von dem Ich nicht schon wüsste.

cu DrLuck

[HerrLehmann]

Die Goldmann Sachs Einstufung von bastiman habe ich in mindestens
vier, vielleicht sogar sieben Threats gelesen.
Ich kriege dabei ein ganz mulmiges Gefühl.

[DrLuck]

Warum ein mulmiges Gefühl?

cu DrLuck

[maik65]

Ich kann die Internetadresse von british Biotech nirgends finden. wer kann helfen ????
Danke im voraus.

[SDT]

Bisher war`s immer http://www.britbio.co.uk/. Scheint nur nicht (mehr) zu funktionieren.

[DrLuck]

Das kann ich gar nicht glauben. Seid Ihr Blind. Schaut mal 5 Postings nach oben.

cu DrLuck

[SDT]

DrLuck,

!

Habe ich tatsächlich nicht gesehen...

[DrLuck]

--------------------------------------------------------------------------------



Thursday September 21, 7:05 am Eastern Time
Press Release
British Biotech plc Chairman`s Statement at Annual General Meeting
OXFORD, England--(BUSINESS WIRE)--Sept. 21, 2000--The Chairman of British Biotech, Mr Christopher Hampson, made the following statement at the Annual General Meeting of shareholders of the Company today:

Since I spoke to you at the last AGM, your Company has concentrated on implementing the strategy I outlined last year. I believe substantial progress has been made and, as a result, a strong platform has been created on which your Company can continue to build. The strategy is to:

exploit our proprietary metalloenzyme inhibition programs;
discover and develop new classes of antibiotics;
develop specialist drugs for the treatment of cancer and inflammation; and
operate in both USA and Europe
This strategy will lead to the development of a product portfolio with innovative new opportunities, in cancer, infection and inflammation both from internal research and external sources. Expansion of the portfolio is a key element of the Company`s strategy and is essential to produce sufficient drug development opportunities to allow for the product failures that are inevitable in our business. We shall continue to add new products to our portfolio by collaboration with third parties and through our own research activities.

One year ago the Company had three products in development. Over the past 12 months we have doubled the portfolio which I will now briefly describe.

Turning to the first three products. In September 1999 we established a collaboration with Schering-Plough to develop and commercialize matrix metalloproteinase inhibitors for cancer, including marimastat. This provided both endorsement for the overall program and contributed to funding for the business. We have now had results from four clinical studies with marimastat and, while each study has failed its primary end-point, there has been some evidence of clinical activity both in patients with gastric cancer and in patients with less extensive disease. Results from two Phase III studies in small cell lung cancer are expected later this year or early in 2001 and are likely to determine the future for marimastat. In the meantime, a Phase I maximum tolerated dose study with BB-3644, a second-generation MMPI for the treatment of cancer, started in November 1999. Manufacture of BB-10153, a clot-dissolving drug, has been outsourced while the Company seeks a partner to develop and commercialize this agent.

Three new compounds have been added to our development portfolio. Two emerged from British Biotech`s own research activities, exceeding last year`s objective of one compound. These compounds are BB-2827, a collagenase inhibitor for rheumatoid arthritis, and BB-76163, an aminopeptidase inhibitor for serious inflammatory disease. The third new product is huN901-DM1, a targeted cytotoxic for the treatment of small cell lung cancer discovered by ImmunoGen Inc., a company based in Boston. This is the first product to be in-licensed by British Biotech. We will jointly develop it in collaboration with ImmunoGen and, in return, have received the rights to commercialize the product in Europe and Japan.

The Company intends to realize value from its products principally through forming development and marketing collaborations with pharmaceutical or other biotechnology companies. British Biotech will, however, retain commercialization rights for the treatment of niche markets.

In the last quarter, the Company downsized and reorganized to concentrate resources on drug development while maintaining a core research capability targeting metalloenzymes. Our research is now focused on new classes of antibiotics needed to overcome the problems of bacterial resistance. The lead program targets a bacterial metalloenzyme, polypeptide deformylase, and is anticipated to produce a compound for development by the end of the year. I am pleased to say that our Company has the first published patent in this field. To increase the chemical diversity of our anti-bacterial program, we have recently entered into a collaboration with De Novo Pharmaceuticals, a Cambridge-based company specializing in molecular design.

As a critical part of the reorganization, the Company`s Research and Development have been integrated. We have established a strong development capability with the expertise to undertake product development in North America and Europe. We believe, as exemplified by the collaboration with ImmunoGen, that this capability makes us an attractive partner for many biotech and small pharmaceutical companies, particularly in the USA.

External consultation is fundamental to the operation of our business. A Scientific Advisory Board made up of international experts is consulted on the Company`s research and development programs. In addition, collaborations have been established with outside companies such as CareScience and Agilent to enhance key steps in drug development. Furthermore, the Company has appointed an independent Safety Advisory Board to review clinical trials.

In respect of financial management, the cash burn has been reduced to (pound)22 million, compared with (pound)34.5 million in the previous year, resulting in cash balances of (pound)75 million at April 30th. Management action to reorganize and reduce headcount has lowered the fixed-cost base of the business. The Company is well placed to invest in its portfolio over the next three years.

In conclusion the past year has been challenging but has seen the Company establish a strong platform for the future. The portfolio has doubled in size with six products now in development. We have a clear strategy to create and pursue new opportunities to build value for shareholders.

British Biotech

British Biotech is a publicly traded development-stage pharmaceutical Company (LSE: BBG, NASDAQ: BBIOY) which is building a portfolio of products for the treatment of cancer, inflammation and infectious disease. These opportunities will be generated from in-house research and development and by acquisition from, and collaboration with, outside parties.

British Biotech currently has six products in development. Marimastat, a matrix metalloproteinase inhibitor, is in Phase III development for the treatment of cancer, BB-3644, a follow-on to marimastat, is in Phase I development for cancer, and BB-10153 has completed Phase I development for cardiovascular disease. BB-2827, a collagenase inhibitor for inflammation, huN901-DM1, a targeted cytotoxic for small cell lung cancer, and BB-76163, an aminopeptidase inhibitor for chronic inflammatory disease, are in preclinical development.

This news release contains forward-looking statements which reflect the Company`s current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company`s research strategy, the applicability of the discoveries made therein, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.


--------------------------------------------------------------------------------
Contact:

British Biotech plc
Tony Weir, 011-44-1865-781166
or
G.A. Kraut Company
Gerard Coffey, 212/696-5600

[DrLuck]

Tuesday September 26, 11:17 am Eastern Time
Press Release
British Biotech plc Results of marimastat Study 186 In Patients With Advanced Ovarian Cancer
OXFORD, England--(BUSINESS WIRE)--September 26, 2000--British Biotech (NASDAQ:BBIOY - news) announces the results of Study 186, a clinical trial of the oral matrix metalloproteinase inhibitor, marimastat. Patients enrolled into the study had advanced ovarian cancer that had failed to respond to at least one prior treatment with carboplatin. The trial was designed to study the effect of marimastat, when given in combination with carboplatin, on these patients.

Treatment with the combination of carboplatin and marimastat showed no statistically significant advantage over carboplatin alone in either primary or secondary endpoints.

This news release contains forward-looking statements which reflect the Company`s current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company`s research strategy, the applicability of the discoveries made therein, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.

Notes to Editors

British Biotech is a research and development stage company (LSE: BBG, NASDAQ: BBIOY). Its strategy is to build shareholder value by exploiting its proprietary programs in metalloenzyme inhibition; discovering and developing new classes of antibiotics; developing specialist drugs for the treatment of cancer and inflammation; and operating in both the USA and Europe.

The Company has six products in development and is actively expanding its portfolio through its own research and collaboration with third parties. Value from products will be realised via development and marketing collaborations with pharmaceutical and biotech companies, and by retaining commercialisation rights to niche markets.

Three products are in clinical development. Marimastat, a matrix metalloproteinase inhibitor, is in Phase III development for the treatment of cancer, BB-3644, a follow-on to marimastat, is in Phase I development for cancer, and BB-10153 has completed Phase I development for cardiovascular disease. BB-2827, a collagenase inhibitor for inflammation, huN901-DM1, a targeted cytotoxic for small cell lung cancer, and BB-76163, an aminopeptidase inhibitor for chronic inflammatory disease, are in preclinical development.


--------------------------------------------------------------------------------
Contact:

British Biotech plc
Tony Weir, Finance Director
011-44-1865-781166
or
G.A. Kraut Company
Gerard Coffey, Vice President
212-696-5600

[ani]

Hi Leute, kann mir jemand das mal übersetzen.
Danke im voraus.

[Cowboy00]

Hi Jungs!

Ein gutgemeinter Rat von mir, lasst die Finger von BBP!
Fühlt Euch nicht in Eurer Ehre verletzt, es ist nur ein guter Rat! Es steht um BBP ungefähr wie um BAAN! Ein tiefer Fall aufgrund eines schlechten Managements!

Gruß Cowboy

[DrLuck]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[User5]

Hallo,
gibt es was neues?
user5

[berlusconi]

Die Analysten von Goldman Sachs stufen British Biotech mit Outperformer ein.

Das Unternehmen habe seine Zahlen für das Gesamtjahr veröffentlicht. Darin sei zu erkennen gewesen, dass der Fokus des Unternehmens im vergangenen Jahr auf Kosteneinsparungsmaßnahmen gelegen gewesen sei. Der Cash Burn sei auf 10,7 Mio. GBP reduziert worden, und die Netto-Cashposition habe zum Jahresende 65 Mio. GBP betragen, was für mindestens drei Jahre ausreiche. Gewisse Rückschläge bei Projekten im Frühstadium hätten durch den Vorteil im klinischen Bereich ausgeglichen werden können.

Nach Einschätzungen der Analysten verfolge das Unternehmen die richtige Strategie; mit potenziellem Newsflow aus klinischen Programmen sei die Aktie einen Blick wert.

Analyst: Goldman Sachs
WKN der Aktie: 884408
KGV 02e: k.A.
Besprechungskurs: k.A.
Kursziel: k.A.
Rating des Analysten: Outperformer




Quelle: Aktienresearch 27.07.2001 12:23

[traumsuse]

Hallo an alle,
kennt jemand die deutschsprachige Website von British Biotech?